| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

27-28 April 2022

Asebio Investor Day

Madrid

Spain

20-21 April 2022

Kempen Life Sciences Conference

Amsterdam

Netherlands

28-31 March 2022

Bio-Europe Spring 2022

25 March 2022

ORYZON to give updates on corporate progress in March and April

21 March 2022

ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients

15-17 March 2022

Barclays Global Healthcare Conference

Miami

FL

United States

8 March 2022

BioMed Event 2022

Paris

France

2 March 2022

Epigenetics Symposium – From Genes to Chromatin to Therapeutics

Philadelphia

PA

United States

14-17 February 2022

BIO CEO & Investor Conference 2022

New York

NY

United States

14 February 2022

ORYZON to give updates on corporate progress in February and March

Pagination

First page «
Previous page ‹
Page 19
Page 20
Page 21
Page 22
Current page 23
Page 24
Page 25
Page 26
Page 27
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel